Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models

Restricted access

OBJECTIVE

Many pharmaceutical agents are highly potent but are unable to exert therapeutic activity against disorders of the central nervous system (CNS), because the blood-brain barrier (BBB) impedes their brain entry. One such agent is bortezomib (BZM), a proteasome inhibitor that is approved for the treatment of multiple myeloma. Preclinical studies established that BZM can be effective against glioblastoma (GBM), but only when the drug is delivered via catheter directly into the brain lesion, not after intravenous systemic delivery. The authors therefore explored alternative options of BZM delivery to the brain that would avoid invasive procedures and minimize systemic exposure.

METHODS

Using mouse and rat GBM models, the authors applied intranasal drug delivery, where they co-administered BZM together with NEO100, a highly purified, GMP-manufactured version of perillyl alcohol that is used in clinical trials for intranasal therapy of GBM patients.

RESULTS

The authors found that intranasal delivery of BZM combined with NEO100 significantly prolonged survival of tumor-bearing animals over those that received vehicle alone and also over those that received BZM alone or NEO100 alone. Moreover, BZM concentrations in the brain were higher after intranasal co-delivery with NEO100 as compared to delivery in the absence of NEO100.

CONCLUSIONS

This study demonstrates that intranasal delivery with a NEO100-based formulation enables noninvasive, therapeutically effective brain delivery of a pharmaceutical agent that otherwise does not efficiently cross the BBB.

ABBREVIATIONS BBB = blood-brain barrier; BZM = bortezomib; cGMP = current good manufacturing practice; CNS = central nervous system; CSF = cerebrospinal fluid; GBM = glioblastoma; HPLC = high-performance liquid chromatography; IS = internal standard; MTT = methylthiazoletetrazolium; NEO100 = enriched perillyl alcohol manufactured under cGMP conditions; POH = perillyl alcohol; TMZ = temozolomide; USC = University of Southern California.
Article Information

Contributor Notes

Correspondence Thomas C. Chen: University of Southern California, Los Angeles, CA. tcchen@usc.edu.INCLUDE WHEN CITING Published online March 15, 2019; DOI: 10.3171/2018.11.JNS181161.Disclosures Dr. Chen reports an ownership interest (founder and stakeholder) in NeOnc Technologies, Los Angeles, CA.

© AANS, except where prohibited by US copyright law.

Headings
References
  • 1

    Agrawal MSaraf SSaraf SAntimisiaris SGChougule MBShoyele SA: Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 281:1391772018

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    Aiello-Laws LRutledge DN: Management of adult patients receiving intraventricular chemotherapy for the treatment of leptomeningeal metastasis. Clin J Oncol Nurs 12:4294352008

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Bota DAAlexandru DKeir STBigner DVredenburgh JFriedman HS: Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells’ VEGF production and angiogenesis. J Neurosurg 119:141514232013

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    Chen TCDa Fonseca COSchönthal AH: Perillyl alcohol and its drug-conjugated derivatives as potential novel methods of treating brain metastases. Int J Mol Sci 17:172016

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Chen TCFonseca COSchönthal AH: Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy. Am J Cancer Res 5:158015932015

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6

    Chen TCWang WGolden EBThomas SSivakumar WHofman FM: Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett 302:1001082011

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Crowe TPGreenlee MHWKanthasamy AGHsu WH: Mechanism of intranasal drug delivery directly to the brain. Life Sci 195:44522018

  • 8

    da Fonseca COSchwartsmann GFischer JNagel JFuturo DQuirico-Santos T: Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 70:2592672008

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9

    da Fonseca COSimão MLins IRCaetano ROFuturo DQuirico-Santos T: Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol 137:2872932011

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10

    da Fonseca COTeixeira RMSilva JCTde Saldanha da Gama Fischer JMeirelles OCLandeiro JA: Long-term outcome in patients with recurrent malignant glioma treated with perillyl alcohol inhalation. Anticancer Res 33:562556312013

    • Search Google Scholar
    • Export Citation
  • 11

    Dhuria SVHanson LRFrey WH II: Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99:165416732010

  • 12

    Djupesland PGMessina JCMahmoud RA: The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv 5:7097332014

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Dréan AGoldwirt LVerreault MCanney MSchmitt CGuehennec J: Blood-brain barrier, cytotoxic chemotherapies and glioblastoma. Expert Rev Neurother 16:128513002016

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Fribley AZeng QWang CY: Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24:969597042004

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15

    Friday BBAnderson SKBuckner JYu CGiannini CGeoffroy F: Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 14:2152212012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Gabay MPThakkar JPStachnik JMWoelich SKVillano JL: Intra-CSF administration of chemotherapy medications. Cancer Chemother Pharmacol 70:1152012

  • 17

    Gross EASwenberg JAFields SPopp JA: Comparative morphometry of the nasal cavity in rats and mice. J Anat 135:83881982

  • 18

    Harkema JRCarey SAWagner JG: The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol 34:2522692006

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    Hemeryck AGeerts RMonbaliu JHassler SVerhaeghe TDiels L: Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. Cancer Chemother Pharmacol 60:7777872007

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20

    Joshi SMeyers PMOrnstein E: Intracarotid delivery of drugs: the potential and the pitfalls. Anesthesiology 109:5435642008

  • 21

    Kardosh AGolden EBPyrko PUddin JHofman FMChen TC: Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res 68:8438512008

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    Labussiere MPinel SDelfortrie SPlenat FChastagner P: Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts. Oncol Rep 20:128312872008

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23

    Meregalli C: An overview of bortezomib-induced neurotoxicity. Toxics 3:2943032015

  • 24

    Nawrocki STCarew JSPino MSHighshaw RADunner K JrHuang P: Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65:11658116662005

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25

    Odia YKreisl TNAregawi DInnis EKFine HA: A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas. J Neurooncol 125:1911952015

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26

    Ostermann SCsajka CBuclin TLeyvraz SLejeune FDecosterd LA: Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10:372837362004

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27

    Portnow JBadie BChen MLiu ABlanchard SSynold TW: The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 15:709270982009

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28

    Quintana DSWestlye LTRustan OGTesli NPoppy CLSmevik H: Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment. Transl Psychiatry 5:e6022015

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29

    Raizer JJChandler JPFerrarese RGrimm SALevy RMMuro K: A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. J Neurooncol 129:1391462016

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30

    Rambabu CVenkatrao SRamu GGanesh M: Estimation of bortezomib in bulk and its pharmaceutical dosage forms by using a novel validated accurate reverse phase high performance liquid chromatography. Int J Pharm Pharm Sci 3:3033052011

    • Search Google Scholar
    • Export Citation
  • 31

    Reger MAWatson GSGreen PSWilkinson CWBaker LDCholerton B: Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70:4404482008

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32

    Richardson PGMitsiades CHideshima TAnderson KC: Proteasome inhibition in the treatment of cancer. Cell Cycle 4:2902962005

  • 33

    Scott KHayden PJWill AWheatley KCoyne I: Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev 4:CD0108162016

  • 34

    Serwer LPJames CD: Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations. Adv Drug Deliv Rev 64:5905972012

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35

    Shingaki THidalgo IJFurubayashi TKatsumi HSakane TYamamoto A: The transnasal delivery of 5-fluorouracil to the rat brain is enhanced by acetazolamide (the inhibitor of the secretion of cerebrospinal fluid). Int J Pharm 377:85912009

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36

    Stupp RMason WPvan den Bent MJWeller MFisher BTaphoorn MJ: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:9879962005

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37

    Styczynski JOlszewska-Slonina DKolodziej BNapieraj MWysocki M: Activity of bortezomib in glioblastoma. Anticancer Res 26 (6B):449945032006

  • 38

    van Tellingen OYetkin-Arik Bde Gooijer MCWesseling PWurdinger Tde Vries HE: Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 19:1122015

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39

    Wang DGao YYun L: Study on brain targeting of raltitrexed following intranasal administration in rats. Cancer Chemother Pharmacol 57:971042006

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40

    Wang FJiang XLu W: Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int J Pharm 263:172003

  • 41

    Wang WCho HYRosenstein-Sisson RMarín Ramos NIPrice RHurth K: Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model. J Neurosurg 128:6957002018

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42

    Zhang YZhu XHou KZhao JHan ZZhang X: Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis. Oncol Rep 33:227722842015

TrendMD
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 8 8 8
Full Text Views 0 0 0
PDF Downloads 0 0 0
EPUB Downloads 0 0 0
PubMed
Google Scholar